Nemera and Therakind have entered into a strategic partnership to accelerate the development of dry powder intranasal drug delivery technologies, combining device engineering and pharmaceutical development capabilities.
The collaboration brings together Nemera’s expertise in the design, development and industrialisation of drug delivery devices with Therakind’s experience in advancing medicines from development through to regulatory approval. At the centre of the agreement is Therakind’s DriDose® platform, a dry powder intranasal device portfolio.
For Nemera, the addition of DriDose® marks an expansion of its nasal delivery offering, which has so far focused on liquid formulations. The move broadens its positioning towards a more comprehensive platform approach, covering both liquid and dry powder delivery.
Therakind, a UK-based pharmaceutical company, will continue to develop and deploy the DriDose® technology across its internal pipeline as well as through collaborations with partners, as part of its focus on combination products.
“We are delighted to partner with Nemera, known for its expertise in drug delivery solutions and novel device industrialisation. As a market leader with a global presence, Nemera is an ideal partner for the industrialisation and expansion of the DriDose® portfolio.” said Dr Susan Conroy, CEO of Therakind, highlighting the group’s expertise in device industrialisation and global reach.
Dimitri Grasswill, Vice President of Nemera’s Ear, Nose and Throat business, pointed to the potential of dry powder delivery to open new therapeutic applications, particularly in areas where unmet needs remain in both systemic and local treatments.
The partnership reflects a broader industry trend towards alternative drug delivery routes, with intranasal technologies attracting increasing interest for their potential in rapid absorption and patient-friendly administration.